SCNX — Scienture Holdings, Inc.
$2.88+3.97%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for SCNX in the TickerWise workspace.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
Company profile
- Sector: Healthcare
- Industry: Medical - Pharmaceuticals
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 14
- Website: https://scienture.com
Latest SEC filings for SCNX
Latest SCNX news
- Scienture Holdings reports preliminary Q3 results Read article
- SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth Read article
- SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals Read article
- Scienture announces 1-for-25 reverse stock split Read article
- Scienture Holdings, Inc. Announces Reverse Stock Split Read article
- MEDS Stock Soars As AI Oncology Bet Ignites Trading Frenzy
- MEDS Stock Rockets As DataMEDS AI Bets Big On Cancer Diagnostics
- MEDS Stock Rockets As DataMEDS AI Bets Big On Cancer And Telehealth
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.